Your browser doesn't support javascript.
loading
Population Genome Programs across the Middle East and North Africa: Successes, Challenges, and Future Directions.
Ateia, Hagar; Ogrodzki, Pauline; Wilson, Hannah V; Ganesan, Subhashini; Halwani, Rabih; Koshy, Ashish; Zaher, Walid A.
Affiliation
  • Ateia H; G42 Healthcare, Masdar City Abu Dhabi, UAE.
  • Ogrodzki P; IROS (Insights Research Organization and Solutions), Abu Dhabi, UAE.
  • Wilson HV; G42 Healthcare, Masdar City Abu Dhabi, UAE.
  • Ganesan S; IROS (Insights Research Organization and Solutions), Abu Dhabi, UAE.
  • Halwani R; G42 Healthcare, Masdar City Abu Dhabi, UAE.
  • Koshy A; IROS (Insights Research Organization and Solutions), Abu Dhabi, UAE.
  • Zaher WA; Sharjah University, Sharjah, UAE.
Biomed Hub ; 8(1): 60-71, 2023.
Article in En | MEDLINE | ID: mdl-37900972
ABSTRACT
In this review, we discuss the current state of population genome programs (PGPs) conducted in the Middle East and North African (MENA) region. This region has high prevalence of genetic diseases and significant health challenges as well as being a significantly underrepresented population in public genetic databases. The majority of ongoing PGPs represent regions in Europe, North and South America, South Asia, Australia, and Africa, with little to no descriptive information highlighted only on the MENA Region when it comes to genome programs databases, outcomes, or the challenges that MENA region countries may face establishing their own national programs. This review has identified 6 PGPs currently underway in the MENA region, namely in the Kingdom of Saudi Arabia, Qatar, Egypt, the United Arab Emirates, Bahrain, and Iran. Due to the rapidly growing involvement of the MENA region in national-scale genomic data collection, an increase in representation in public genetic databases is to be expected to occur in the near future. Whilst significant progress is being made in some MENA countries, future initiatives as well as ongoing programs will be facing several challenges related to collaboration, finance, infrastructure and institutional data access, data analysis, sustainability, health records, and biobanks. The review also reiterates the need for ensuring ethical and regulated genomic initiatives which can drive developments in personalized medicine treatments to improve patient prognosis and quality of life.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Biomed Hub Year: 2023 Document type: Article Publication country: CH / SUIZA / SUÍÇA / SWITZERLAND

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Biomed Hub Year: 2023 Document type: Article Publication country: CH / SUIZA / SUÍÇA / SWITZERLAND